14 May 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
27 May 2020
New facilities available for Oncode researchers
We are pleased to announce that three facilities are now open to the whole Oncode research community. The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Instead of competition between scientists, Oncode encourages collaboration. Investing in facilities which can be used by all Oncode researchers, is one of the ways in which Oncode wants to contribute to breakthroughs in cancer research.
22 May 2020
In Memoriam: Professor Huib Ovaa
On the 19th of May 2020, our dear colleague Professor Dr. Huib Ovaa passed away from prostate cancer. In the past year, Huib has undergone a variety of treatments, and has done so with his usual optimism. He continued to work as much as possible and tried to keep the burden of his fight against cancer away from the people around him. Huib was 46 years of age.
15 May 2020
Oncode Institute is in Top 50 NPO/NGOs ranked by Nature Index
We are honoured to announce that Nature Index included Oncode Institute in its Top 50 NPO/NGO institutions in cancer research worldwide. Every year, Nature Index publishes its Cancer supplement, featuring a list of the most prominent institutes and academic, healthcare, NPO/NGO, government and corporate institutions working in cancer research.
30 April 2020
Insight into Making Scientific Findings Publicly Available
Preprint servers like BioRxiv or MedRxiv are tools that can be combined with traditional peer reviewed journals to increase impact and visibility. Until 2019, only around 5% of publications by Oncode Investigators were shared via a preprint server before being published in a peer reviewed journal, whether OA or subscription. We spoke to Oncode Investigator Lude Franke (UMCG) about how publishing on BioRxiv strongly impacted his research.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more